Barricaid Completes $52MM Financing to Support Barricaid

Intrinsic Therapeutics completed a US $52MM Series Growth equity financing. Proceeds will support U.S. commercialization of the Barricaid® anular closure device, which is used after discectomy to treat herniated discs. In all, the company has raised ~$219MM in over 10 rounds of funding to date.

The company received FDA Premarket Approval for...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us